The pharmaceutical community is intrigued by retatrutide, a novel dual GIP and GLP-1 agonist that’s showing remarkable results in early trials . This treatment works by imitating natural hormones to regulate appetite and boost feelings of fullness , ultimately contributing to substantial weight r